Chelsea C Pinnix1, Laura Cella2, Therese Y Andraos3, Zeina Ayoub3, Sarah A Milgrom3, Jillian Gunther3, Sonali Thosani4, Christine Wogan3, Manuel Conson5, Vittoria D'Avino2, Yasuhiro Oki6, Michelle Fanale6, Hun J Lee6, Sattva Neelapu6, Luis Fayad6, Frederick Hagemeister6, M Alma Rodriguez6, Loretta J Nastoupil6, Yago Nieto7, Wei Qiao8, Roberto Pacelli5, Bouthaina Dabaja3. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ccpinnix@mdanderson.org. 2. Institute of Biostructures and Bioimaging, National Research Council (CNR), Naples, Italy. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Advanced Biomedical Sciences, Federico II University School of Medicine, Naples, Italy. 6. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: To identify predictors of hypothyroidism after chemoradiation therapy for Hodgkin lymphoma (HL) and to compare outcomes after intensity modulated radiation therapy (IMRT) with those after 3-dimensional (3D) conformal radiation therapy (CRT). METHODS AND MATERIALS: Ninety patients who underwent involved-site IMRT in 2009 through 2014 were evaluated for treatment-induced hypothyroidism, defined as elevated thyroid-stimulating hormone or decreased free thyroxine levels (or both). Receiver operating characteristic curve analysis identified individuals at low versus high risk based on dosimetric variables. Dosimetric cutoff points were verified with an external data set of 50 patients who underwent 3D-CRT. RESULTS: In the IMRT group, most patients (75 [83%]) had stage II HL, and the median prescribed dose was 30.6 Gy; in the 3D-CRT group, 32 patients (64%) had stage II HL, and the median prescribed dose was 32.0 Gy. No differences were found in the proportions of patients with bilateral (P = .982) or unilateral (P = .074) neck involvement between the 2 groups. Hypothyroidism rates were marginally higher in the IMRT group, with estimated 3-year rates of freedom from hypothyroidism of 56.1% in the 3D-CRT group and 40% in the IMRT group (P = .057). Univariate analysis showed that smaller thyroid volume and higher thyroid dose were associated with hypothyroidism in both groups (P < .05). In the IMRT group, the percentage of the thyroid gland volume receiving ≥25 Gy (V25) and the absolute volume of the thyroid gland spared from 25 Gy (VS25Gy) were the strongest predictors of hypothyroidism (P = .001 and P < .001, respectively). Cutoff points of 63.5% (V25) and 2.2 mL (VS25Gy) classified patients as high risk (80%-82%) or low risk (37%-44%) (P < .001). Use of a thyroid avoidance structure reduced the incidence of hypothyroidism (P < .05) in the IMRT group. CONCLUSIONS: The percentage of the thyroid receiving 25 Gy and the volume of the thyroid spared from 25 Gy predicted the risk of hypothyroidism after either IMRT or 3D-CRT for HL. IMRT may confer a higher risk than 3D-CRT unless a treatment avoidance structure is used during planning.
PURPOSE: To identify predictors of hypothyroidism after chemoradiation therapy for Hodgkin lymphoma (HL) and to compare outcomes after intensity modulated radiation therapy (IMRT) with those after 3-dimensional (3D) conformal radiation therapy (CRT). METHODS AND MATERIALS: Ninety patients who underwent involved-site IMRT in 2009 through 2014 were evaluated for treatment-induced hypothyroidism, defined as elevated thyroid-stimulating hormone or decreased free thyroxine levels (or both). Receiver operating characteristic curve analysis identified individuals at low versus high risk based on dosimetric variables. Dosimetric cutoff points were verified with an external data set of 50 patients who underwent 3D-CRT. RESULTS: In the IMRT group, most patients (75 [83%]) had stage II HL, and the median prescribed dose was 30.6 Gy; in the 3D-CRT group, 32 patients (64%) had stage II HL, and the median prescribed dose was 32.0 Gy. No differences were found in the proportions of patients with bilateral (P = .982) or unilateral (P = .074) neck involvement between the 2 groups. Hypothyroidism rates were marginally higher in the IMRT group, with estimated 3-year rates of freedom from hypothyroidism of 56.1% in the 3D-CRT group and 40% in the IMRT group (P = .057). Univariate analysis showed that smaller thyroid volume and higher thyroid dose were associated with hypothyroidism in both groups (P < .05). In the IMRT group, the percentage of the thyroid gland volume receiving ≥25 Gy (V25) and the absolute volume of the thyroid gland spared from 25 Gy (VS25Gy) were the strongest predictors of hypothyroidism (P = .001 and P < .001, respectively). Cutoff points of 63.5% (V25) and 2.2 mL (VS25Gy) classified patients as high risk (80%-82%) or low risk (37%-44%) (P < .001). Use of a thyroid avoidance structure reduced the incidence of hypothyroidism (P < .05) in the IMRT group. CONCLUSIONS: The percentage of the thyroid receiving 25 Gy and the volume of the thyroid spared from 25 Gy predicted the risk of hypothyroidism after either IMRT or 3D-CRT for HL. IMRT may confer a higher risk than 3D-CRT unless a treatment avoidance structure is used during planning.
Authors: Laura Cella; Manuel Conson; Michele Caterino; Nicola De Rosa; Raffaele Liuzzi; Marco Picardi; Francesco Grimaldi; Raffaele Solla; Antonio Farella; Marco Salvatore; Roberto Pacelli Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-20 Impact factor: 7.038
Authors: Laura Cella; Vittoria D'Avino; Giuseppe Palma; Manuel Conson; Raffaele Liuzzi; Marco Picardi; Maria Cristina Pressello; Genoveva Ionela Boboc; Roberta Battistini; Vittorio Donato; Roberto Pacelli Journal: Radiother Oncol Date: 2015-08-12 Impact factor: 6.280
Authors: Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-18 Impact factor: 7.038
Authors: Chelsea C Pinnix; Grace L Smith; Sarah Milgrom; Eleanor M Osborne; Jay P Reddy; Mani Akhtari; Valerie Reed; Isidora Arzu; Pamela K Allen; Christine F Wogan; Michele A Fanale; Yasuhiro Oki; Francesco Turturro; Jorge Romaguera; Luis Fayad; Nathan Fowler; Jason Westin; Loretta Nastoupil; Fredrick B Hagemeister; M Alma Rodriguez; Sairah Ahmed; Yago Nieto; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-01 Impact factor: 7.038
Authors: Brian Hung-Hin Lang; Carlos K H Wong; Kai Pun Wong; Kelvin Ka-Wan Chu; Tony W H Shek Journal: Ann Surg Oncol Date: 2017-01-05 Impact factor: 5.344
Authors: Grace L Smith; Benjamin D Smith; Adam S Garden; David I Rosenthal; Steven I Sherman; William H Morrison; David L Schwartz; Randal S Weber; Thomas A Buchholz Journal: Head Neck Date: 2009-08 Impact factor: 3.147
Authors: Alice J Sigurdson; Cécile M Ronckers; Ann C Mertens; Marilyn Stovall; Susan A Smith; Yan Liu; Roger L Berkow; Sue Hammond; Joseph P Neglia; Anna T Meadows; Charles A Sklar; Leslie L Robison; Peter D Inskip Journal: Lancet Date: 2005 Jun 11-17 Impact factor: 202.731
Authors: Bouthaina Shbib Dabaja; Bradford S Hoppe; John P Plastaras; Wayne Newhauser; Katerina Rosolova; Stella Flampouri; Radhe Mohan; N George Mikhaeel; Youlia Kirova; Lena Specht; Joachim Yahalom Journal: Blood Date: 2018-08-14 Impact factor: 22.113
Authors: Andrea Riccardo Filippi; Sofia Meregalli; Anna DI Russo; Mario Levis; Patrizia Ciammella; Michela Buglione; Andrea Emanuele Guerini; Giuseppina De Marco; Vitaliana De Sanctis; Stefano Vagge; Umberto Ricardi; Gabriele Simontacchi Journal: Radiat Oncol Date: 2020-03-12 Impact factor: 3.481
Authors: Chelsea C Pinnix; Jillian R Gunther; Penny Fang; Mikaela E Bankston; Sarah A Milgrom; David Boyce; Hun Ju Lee; Ranjit Nair; Raphael Steiner; Paolo Strati; Sairah Ahmed; Swaminathan P Iyer; Jason Westin; Simrit Parmar; M Alma Rodriguez; Loretta Nastoupil; Sattva Neelapu; Christopher Flowers; Bouthaina S Dabaja Journal: JAMA Netw Open Date: 2020-09-01